πŸ”¬Deep Research

IDXX β€” IDEXX Laboratories Β· catalysts, narrative & risks

Β·27 sourcesIDXX forecast β†’

IDEXX Laboratories (IDXX) β€” Research Snapshot as of 2026-10-03

Listing / classification: NASDAQ (S&P 500 member), filed under animal_health. [22][23][24]


Key Recent Catalysts (July–October 2026)

1. Q2 2026 earnings beat (reported August 4, 2026). IDEXX reported diluted EPS of $4.27 (up ~18% year-over-year, beating the Zacks Consensus estimate by ~8.1%) and revenue of $1.22 billion (up ~10%), exceeding consensus on both lines. Companion Animal Group (CAG) Diagnostics recurring revenues rose 11% as reported / 10% organically. [10][18][23][24]


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’